Arcutis Biotherapeutics Revenue and Competitors



Total Funding



Estimated Revenue & Valuation

  • Arcutis Biotherapeutics's estimated annual revenue is currently $27.6M per year.(i)
  • Arcutis Biotherapeutics's estimated revenue per employee is $87,310
  • Arcutis Biotherapeutics's total funding is $583.5M.
  • Arcutis Biotherapeutics's current valuation is $216M. (October 2023)

Employee Data

  • Arcutis Biotherapeutics has 316 Employees.(i)
  • Arcutis Biotherapeutics grew their employee count by 17% last year.

Arcutis Biotherapeutics's People

Chief Staff, Head ESGReveal Email/Phone
VP BiometricsReveal Email/Phone
Head Core Technology and SecurityReveal Email/Phone
VP Regulatory AffairsReveal Email/Phone
VP QualityReveal Email/Phone
Head Tax and Risk ManagementReveal Email/Phone
Head Investor RelationsReveal Email/Phone
VP, R&D StrategyReveal Email/Phone
Head Data, Analytics and Digital InnovationReveal Email/Phone
VP Finance, Corporate ControllerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
Add Company

What Is Arcutis Biotherapeutics?

Arcutis (Nasdaq: ARQT) was founded in 2016 to address significant unmet needs in medical dermatology. The company is a clinical-stage biopharmaceutical company focused on developing and commercializing best-in-class products. Our strategy is to exploit recent innovations in inflammation and immunology to bring the best molecules to bear against validated physiologic targets known to treat dermatological diseases and disorders. Our management team has extensive expertise in the development and commercialization of medical dermatology products, having held key leadership roles at a number of leading dermatology companies and, collectively, has successfully developed more than 50 FDA-approved products. We believe that by leveraging our teamᅢᄁ¬ツᆲ¬トᄁs unique experience and demonstrated expertise to identify, develop and commercialize best-in-class molecules against validated targets, we will be able to develop differentiated products in less time, at lower cost, and at substantially lower risk than other approaches. Arcutis' combination of vision, unmet medical need, experienced management and strategic approach has attracted support from leading investors in the life sciences sector.



Total Funding


Number of Employees


Revenue (est)


Employee Growth %





Arcutis Biotherapeutics News

2021-11-04 - Arcutis Announces Third Quarter 2021 Financial Results and Provides Business Update - Form 8-K

Arcutis Announces Third Quarter 2021 Financial Results and Provides Business Update •Submitted New Drug Application (NDA) for roflumilast cream for the treatment of plaque psoriasis across the full spectrum of disease •Initiated single pivotal Phase 3 trial of roflumilast foam in scalp and bod ...

2020-07-16 - ARCUTIS BIOTHERAPEUTICS, INC. Arcutis Biotherapeutics : The New England Journal of Medicine Publishes Results from Positive Phase 2b Trial of Arcutis' ARQ-151 (Topical Roflumilast Cream) for the Treatment of Chronic Plaque Psoriasis

Data demonstrate potential “Best in Class” topical PDE4 inhibitor roflumilast significantly improves chronic plaque psoriasis Phase 3 topline data anticipated first half of 2021 WESTLAKE VILLAGE, Calif., July 15, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stag ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding